THE NEED
One in eight persons age 65 and over and nearly half of the 85+ population have Alzheimer’s disease. Despite intensive efforts by the scientific and pharmaceutical communities throughout the world, Alzheimer’s disease is still unpreventable, largely untreatable, and incurable. Moreover, today diagnosis is typically carried out through clinical assessments at advanced stages of the disease when damage is significant and the potential for delaying disease progression is low. To date, no objective, accurate tool for diagnosing Alzheimer’s or any other neurodegenerative disease exists.

 

The U.S. National Institutes of Health: “Early diagnosis of AD benefits affected individuals and their families, clinicians, and researchers. For patients and their families, a definitive early diagnosis provides the opportunity to plan for the future while the patient can still take an active role in decision making. For clinicians, accurate early diagnosis facilitates the selection of appropriate treatments, particularly as new interventions are developed to stop or slow progression of symptoms. And for researchers, earlier and more accurate diagnosis will facilitate clinical studies of new therapies and preventive measures by allowing clinical trials on early intervention, before cognitive loss becomes significant.”

 

 

THE NEUROQUEST BREAKTHROUGH
NeuroQuest’s patent pending technology is based on the award-winning research of neurodegenerative disease pathology of Professor Michal Schwartz of the Weizmann Institute of Science in Israel. In contrast to prevailing thought, Prof. Schwartz found that immune cells from the periphery are needed for maintaining proper activity of the brain and for healing and repair following damage. Changes in these immune cells’ activity may increase the susceptibility to develop neurodegenerative diseases. As a result changes in immune cells in the peripheral blood precede disease related functional loss, and therefore can be detected before cognitive loss becomes significant. Accordingly, these typical cellular changes can be used as biomarkers for earlier diagnosis of Alzheimer’s disease.

 

 

BUSINESS DEVELOPMENT
The Company will develop the following products:

 

 

Definitive          End of 2010            2012        2012

 

Early                Collaborations         2014        2015

Diagnosis         starting 2011

 

 

Prof. Michal Schwartz, Ph.D., Scientific Advisor, Co-Founder. World-renowned scientist; professor, Dept. of Neurobiology, Weizmann Institute of Science; joint faculty position, Cedar Sinai Medical Center; founder, Proneuron Biotechnologies, Inc.; extensive honors/prizes, publications/presentations; Ph.D., chemical immunology, Weizmann Institute

Eti Yoles, Ph.D., Managing Director. Years of high-level experience in managing research and biotech development; VP R&D, Proneuron Biotechnologies, Inc.; scientist in Dr. Schwartz’s laboratory at the Weizmann Institute; involved in numerous research projects, widely published, guest lecturer in courses of worldwide scientific associations; Ph.D., neurobiology, Bar-Ilan University

Esti Adan, VP Business Development. More than 20 years in high-tech industry, including six years
as successful business development director in Silicon Valley, responsible for generating significant revenues from large software vendors; B.Sc., software engineering, Technion-Israel Institute of Technology

Steve Rhodes, MBA, Chairman of the Board. Extensive finance, marketing, and management experience; CEO, Misgav Venture Accelerator since 2004; cofounder, The Trendlines Group, one of Israel’s leading early-stage investors; MBA, University of Chicago, B.A., Harvard University